XY Capital Ltd Invests $1.06 Million in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

XY Capital Ltd acquired a new position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 67,209 shares of the company’s stock, valued at approximately $1,061,000. Dr. Reddy’s Laboratories makes up 0.5% of XY Capital Ltd’s investment portfolio, making the stock its 19th largest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of RDY. Farther Finance Advisors LLC increased its stake in shares of Dr. Reddy’s Laboratories by 43.2% in the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after purchasing an additional 322 shares in the last quarter. Lifestyle Asset Management Inc. increased its stake in shares of Dr. Reddy’s Laboratories by 3.2% in the third quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company’s stock worth $1,088,000 after purchasing an additional 422 shares in the last quarter. GAMMA Investing LLC grew its holdings in Dr. Reddy’s Laboratories by 83.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock valued at $115,000 after buying an additional 657 shares in the last quarter. Finally, Natixis Advisors LLC grew its holdings in Dr. Reddy’s Laboratories by 7.2% during the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock valued at $869,000 after buying an additional 735 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Trading Down 0.4 %

RDY opened at $13.89 on Monday. The firm has a market cap of $11.59 billion, a P/E ratio of 22.12 and a beta of 0.50. Dr. Reddy’s Laboratories Limited has a 12 month low of $13.36 and a 12 month high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $14.78 and a 200 day moving average of $15.37.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, research analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on RDY. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Finally, Barclays cut their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.